急性髓系白血病 (AML) 结局不佳的最重要原因是复发。假设白血病干细胞 (LSC) 会引发复发，高 CD34 CD38-LSC 负载与不良预后相关。在 10% 的 AML 患者中，白血病细胞上不表达 CD34 或表达水平较低 (<1%)，并且不存在 CD34 CD38-LSC。这些患者被归类为 CD34 阴性。我们的目的是确定原始标记 CD133 是否可以检测 CD34 阴性 AML 中的 LSC。我们回顾性地量化了 HOVON102 和 HOVON132 试验中 148 名 CD34 阴性患者的 CD34 阴性患者诊断样本中 CD34-CD133 和 CD133 CD38- 细胞分数的比例。 CD34-CD133 比例高或低的患者之间没有发现预后差异，而 CD34-CD133 被发现在 AML 中异常表达。高水平的 CD133 CD38- 细胞与较差的总体生存率无关，并且 AML 中的表达与正常骨髓相似。总之，CD133 可作为检测 CD34 阴性 AML 中白血病母细胞的附加原始标记。然而，CD133 CD38 单独不适用于诊断时检测 LSC。© 2024 作者。细胞计数 B 部分：临床细胞计数由 Wiley periodicals LLC 代表国际临床细胞计数协会出版。

The most important reason for dismal outcomes in acute myeloid leukemia (AML) is the development of relapse. Leukemia stem cells (LSCs) are hypothesized to initiate relapse, and high CD34+CD38- LSC load is associated with poor prognosis. In 10% of AML patients, CD34 is not or is low expressed on the leukemic cells (<1%), and CD34+CD38- LSCs are absent. These patients are classified as CD34-negative. We aimed to determine whether the primitive marker CD133 can detect LSCs in CD34-negative AML. We retrospectively quantified 148 CD34-negative patients for proportions of CD34-CD133+ and CD133+CD38- cell fractions in the diagnostic samples of CD34-negative patients in the HOVON102 and HOVON132 trials. No prognostic difference was found between patients with high or low proportions of CD34-CD133+, which is found to be aberrantly expressed in AML. A high level of CD133+CD38- cells was not associated with poor overall survival, and expression in AML was similar to normal bone marrow. To conclude, CD133 is useful as an additional primitive marker for the detection of leukemic blast cells in CD34-negative AML. However, CD133+CD38 alone is not suitable for the detection of LSCs at diagnosis.© 2024 The Author(s). Cytometry Part B: Clinical Cytometry published by Wiley Periodicals LLC on behalf of International Clinical Cytometry Society.